SCIENCE DRIVEN SOLUTIONS FOR RESPIRATORY CARE
At Lallemand Pharma, we are dedicated to advancing respiratory health through innovative, clinically supported solutions. Our products, PMBL™ and Healsea™, are designed to address the prevention and treatment of acute and chronic respiratory conditions.
PMBL™, an immunostimulant drug, is manufactured in a GMP‑certified pharmaceutical facility and is used to help prevent respiratory tract infections.
The Healsea™ medical device nasal spray range is enriched with Symbiofilm™, a unique postbiotic derived from proprietary Lallemand marine bacteria. It offers advanced antibiofilm activity and helps limit viral adhesion. Thanks to its film‑forming properties, certain formulations are intended for the treatment of nasal symptoms associated with colds and flu in both children and adults, while others are indicated for the prevention of upper respiratory tract infections, as well as for the treatment of seasonal allergies and chronic rhinosinusitis.
At Lallemand Pharma, we believe that collaboration drives innovation. If you share our commitment to improving respiratory health worldwide, we welcome the opportunity to work together.
To learn more, visit Lallemand Pharma website.